clinical trial · NCT07140939
A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat
Caliway Biopharmaceuticals Co., Ltd.·phase3·recruiting·n = 320
Subcutaneous FatCBL-514 Injection0.9% Sodium Chloride
brief summary
A phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat.
started
Sep 1, 2026
primary completion
Jul 1, 2027
completion
Sep 1, 2027
last updated
Sep 22, 2026
detailed description
A total of approximately 320 adult participants with moderate or severe abdominal fat at Baseline will be enrolled. Each participant will receive up to 4 treatments of allocated study drug administered subcutaneously to the abdomen, once every 4 weeks.
official title
A Phase 3, Randomized, Double-blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol